ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

desloratadine

Also written as “Desloratadine”, “Desloratadine 5 mg” and “Desloratadine 5 mg (Clarinex)”.

Its studies are mostly in Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Urticaria · Hypersensitivity · Chronic Urticaria, led by 6 companies.

Drug pageDesloratadine: every studyMany companies study it; this page follows only the 39 they lead. All 55 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 4, 200639 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon270 open or runningphase 4since Apr 4, 2006Apr 4, 2006none ahead
Dr. Reddy's Laboratoriesits history only60 open or runningphase 1since Mar 11, 2011Mar 11, 2011none ahead
EMSits history only30 open or runningphase 3since Feb 6, 2012Feb 6, 2012none ahead
Ache Laboratorios Farmaceuticosits history only10 open or runningphase 3since Mar 8, 2016Mar 8, 2016none ahead
Eurofarma Laboratoriosits history only10 open or runningphase 3since Dec 13, 2021Dec 13, 2021none ahead
Laboratorios Silanes S.A. de C.V.its history only10 open or runningphase 3since Apr 1, 2025Apr 1, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 4, 2006First study: phase 4 study in Conjunctivitis, AllergicFirst studyNCT00311844 · 41 enrolled
  2. Jul 31, 2006Phase 4 study in HypersensitivityNCT00359138 · 36 enrolled
  3. Sep 10, 20082 phase 4 studies in UrticariaNCT00751218, NCT00751166
  4. Sep 22, 2008Phase 3 study in Chronic UrticariaNCT00757562 · 97 enrolled
  5. Oct 23, 20086 phase 4 studiesNCT00780403, NCT00779636, NCT00779116 and 3 more
  6. Nov 19, 20084 phase 4 studiesNCT00795522, NCT00794846, NCT00794599 and 1 more
  7. Nov 19, 20083 phase 3 studiesNCT00794794, NCT00794378, NCT00795158
  8. Dec 5, 2008Phase 4 study in Rhinitis, Allergic, SeasonalNCT00805584 · 311 enrolled
  9. Dec 5, 2008Phase 3 study in Rhinitis, Allergic, SeasonalNCT00805324 · 54 enrolled
  10. Jan 5, 2009Phase 3 study in Dermatitis, AtopicNCT00817076 · 40 enrolled
  11. Jan 5, 2009Phase 2 study in Rhinitis, Allergic, SeasonalNCT00816972 · 540 enrolled
  12. Mar 20, 2009Phase 4 study in Rhinitis, Allergic, SeasonalNCT00867191 · 233 enrolled
  13. Aug 2, 20133 phase 3 studiesNCT01916980, NCT01916967, NCT01918033
  14. Dec 15, 2014Phase 3 study in Rhinitis, Allergic, SeasonalNCT02320396 · 449 enrolled

TargetBeta

HRH1 →read by rule
“Histamine H1 receptor antagonist”ChEMBL 37, by rule

Other programs on HRH1

ProgramCompanyFurthest phaseStudies
fexofenadineruleSanofiphase 438
bilastinerulefaes-farma-s-aphase 419
DiphenhydramineruleJohnson & Johnsonphase 416

Studies

All 27 Organon leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02320396Rhinitis, Allergic, Seasonal3CompletedApr 27, 2015449
NCT01918033Rhinitis, Allergic, Perennial3CompletedJan 26, 2014608
NCT01916980Eczema3CompletedMar 8, 201494
NCT01916967Urticaria3CompletedFeb 28, 2014239
NCT00867191Rhinitis, Allergic, Seasonal4CompletedApr 1, 2003233
NCT00817076Dermatitis, Atopic3CompletedJul 200340
NCT00816972Rhinitis, Allergic, Seasonal2CompletedJun 2005540
NCT00805584Rhinitis, Allergic, Seasonal4CompletedJun 2003311
NCT00805324Rhinitis, Allergic, Seasonal3CompletedAug 200354
NCT00795158Urticaria3CompletedJan 2004282
NCT00795522Urticaria4CompletedFeb 200551
NCT00794846Rhinitis, Allergic, Seasonal4CompletedMay 2003124
NCT00794794Rhinitis, Allergic3CompletedNov 2004204
NCT00794599Rhinitis, Allergic, Seasonal4CompletedAug 2003118
NCT00794495Rhinitis, Allergic, Seasonal4CompletedJul 2003122
NCT00794378Rhinitis, Allergic3CompletedNov 2004202
NCT00783354Urticaria4CompletedFeb 1, 2004129
NCT00783211Rhinitis, Allergic, Seasonal4CompletedOct 1, 2004722
NCT00783146Rhinitis, Allergic, Seasonal4CompletedOct 1, 2004728
NCT00780403Hypersensitivity4CompletedOct 2005220
NCT00779636Allergic Airway Disease4CompletedNov 1, 2004506
NCT00779116Hypersensitivity4CompletedOct 2005217
NCT00757562Chronic Urticaria3CompletedOct 1, 200397
NCT00751218Urticaria4CompletedMay 24, 2005174
NCT00751166Urticaria4TerminatedMay 1, 2005149
NCT00359138Hypersensitivity4CompletedMay 200636
NCT00311844Conjunctivitis, Allergic4CompletedMay 28, 200541

How it is read

Names in the registry

  • “Desloratadine”, 12 entries
  • “desloratadine”, 11 entries
  • “Desloratadine 5 mg”, 3 entries
  • “Desloratadine 5 mg (Clarinex)”, 3 entries
  • “Desloratadine + Prednisolone”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.